Aerovate Therapeutics (AVTE)
(Delayed Data from NSDQ)
$24.58 USD
+1.56 (6.78%)
Updated Jun 13, 2024 04:00 PM ET
After-Market: $24.56 -0.02 (-0.08%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth F Momentum F VGM
Brokerage Reports
Aerovate Therapeutics, Inc. [AVTE]
Reports for Purchase
Showing records 1 - 20 ( 40 total )
Company: Aerovate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Aerovate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Breathing Easy Ahead of IMPAHCT Data -- Thoughts on ATS Presentation
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Aerovate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Aerovate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Aerovate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Ready For IMPAHCT --- Final Thoughts Ahead Of Upcoming AV-101 Data
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Aerovate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Aerovate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Assuming Coverage: Ready To Make An IMPAHCT In 2024 With AV-101
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Aerovate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
IMPAHCT Ph2b Completes Enrollment, Topline Ph2b Results in June 2024
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Aerovate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for AVTE 112123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Aerovate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Aerovate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q3: IMPAHCT Ph2b Topline Readout On-Track for Q2:24
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Aerovate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q2:23 Financials; Counting Down to the Ph2b PVR Results for AV-101/PAH in Q2:24
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Aerovate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Aerovate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q1:23 Financials; Enrollment Pace Pushes Ph2b Readout to Q2:24
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Aerovate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Aerovate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
KOL Call Reminder: How stellar is STELLAR? Review of Ph3 sotatercept data @ ACC
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Aerovate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
KOL Call Invite: How stellar is STELLAR? Review of Ph3 sotatercept data at ACC
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Aerovate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2023 Outlook - New Commercial Launches, Clinical Catalysts & M&A Driving Value
Provider: Wedbush Securities Inc.
Analyst: Research Department
Company: Aerovate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Aerovate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Increased Confidence in Inhaled TKIs and AV-101, PT to $54
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A